Randomized, controlled, double-blind, multicenter, prospective clinical study and mechanism exploration of Qinggan Sanjie Xiaoying Decoction in treating Hashimoto's thyroiditis

INTERVENTION: Control Group:Placebo;Research Group:Qinggan Sanjie Xiaoying granule; CONDITION: Hashimoto's thyroiditis PRIMARY OUTCOME: TPOAb; SECONDARY OUTCOME: TGAb;TSH;ultrasound;T4;ThyPRO39;T3;FT4;FT3; INCLUSION CRITERIA: (1)34 IU/ml < TPOAb < 600 IU/ml (2)TGAb < 4000 IU/ml (3)TRAB(‐); (4) Thyroid ultrasound showed diffuse enlargement or heterogeneous echo; (5) 18 to 70 years old; (6) Thyroid hormones (FT3, FT4, T3, T4) were within the reference range; (7) Elevated levels of thyroid stimulating hormone (subclinical hypothyroidism); (8) Drug washout period: no clinical trial, immune preparation and Chinese medicine were conducted within 3 months before enrollment; (9) No drugs affecting thyroid hormone metabolism, including corticosteroids, preparations containing vitamins or trace elements, amiodarone a Interferons, lithium preparations, antidepressants or antipsychotics, etc; (10) Did not participate in other clinical studies; (11) I signed the informed consent to participate in this study.